Originally published as JCO Early Release 10.1200/JCO.2006.07.8972 on May 21 2007

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ansell, S. M. Articles by Borchmann, P. Search for Related Content PubMed PubMed Citation Articles by Ansell, S. M. Articles by Borchmann, P. Social Bookmarking                            What's this?

Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

Stephen M. Ansell, Steven M. Horwitz, Andreas Engert, Khuda Dad Khan, Thomas Lin, Roger Strair, Tibor Keler, Robert Graziano, Diann Blanset, Michael Yellin, Steven Fischkoff, Albert Assad, Peter Borchmann

From the Mayo Clinic School of Medicine, Rochester, MN; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Cologne, Cologne, Germany; American Health Network Oncology, Indianapolis, IN; Ohio State University, Columbus, OH; University of Medicine and Dentistry of New Jersey, Newark; and Medarex Inc, Princeton, NJ

Address reprint requests to Stephen M. Ansell, MD, PhD, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: ansell.stephen{at}mayo.edu

Purpose MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1 monoclonal antibody that inhibits growth of CD30-expressing tumor cells in preclinical models. To determine the safety, maximum-tolerated dose (MTD), and efficacy of MDX-060 in patients with relapsed or refractory CD30+ lymphomas, sequential phase I and II studies were performed.

Patients and Methods In the phase I portion, MDX-060 was administered intravenously at doses of 0.1, 1, 5, or 10 mg/kg weekly for 4 weeks to cohorts of three to six patients. Twenty-one patients—16 with Hodgkin's lymphoma (HL), three with anaplastic large-cell lymphoma (ALCL), and two with CD30+ T-cell lymphoma—were enrolled. Because of the lack of a defined MTD or dose-response correlation, the phase II portion was amended to include several dose levels. In the phase II portion, an additional 51 patients, 47 with HL and four with ALCL, were treated at doses of 1, 5, 10, and 15 mg/kg.

Results MDX-060 was well tolerated, and an MTD has not been identified. Only 7% of patients experienced grade 3 or 4 treatment-related adverse events. Among the 72 patients treated, clinical responses were observed in six. Twenty-five patients had stable disease, including five who remained free from progression 1 year after treatment.

Conclusion MDX-060 was well tolerated at doses up to 15 mg/kg. MDX-060 has limited activity as a single agent, but the minimal toxicity observed and the significant proportion of patients with stable disease suggests that further study of MDX-060 in combination with other therapies is warranted.

published online ahead of print at www.jco.org on May 21, 2007.

S.M.A. and S.M.H. contributed equally to this work.

Presented in part at the 45th Annual Meeting of the American Society of Hematology, December 6-9, 2003, San Diego, CA.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. M. Cardarelli, M.-C. Moldovan-Loomis, B. Preston, A. Black, D. Passmore, T.-H. Chen, S. Chen, J. Liu, M. R. Kuhne, M. Srinivasan, et al. In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma Clin. Cancer Res., May 15, 2009; 15(10): 3376 - 3383. [Abstract] [Full Text] [PDF]

				J. H. Mendler and J. W. Friedberg Salvage Therapy in Hodgkin's Lymphoma Oncologist, April 1, 2009; 14(4): 425 - 432. [Abstract] [Full Text] [PDF]

				B. Pro Novel Agents in Peripheral T-cell Lymphomas ASCO Educational Book, January 1, 2009; 2009(1): 486 - 489. [Abstract] [Full Text] [PDF]

				S. Mercadal, J. Briones, B. Xicoy, C. Pedro, L. Escoda, C. Estany, M. Camos, L. Colomo, I. Espinosa, S. Martinez, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma Ann. Onc., May 1, 2008; 19(5): 958 - 963. [Abstract] [Full Text] [PDF]

				A. Carbone, A. Gloghini, and G. Dotti EBV-Associated Lymphoproliferative Disorders: Classification and Treatment Oncologist, May 1, 2008; 13(5): 577 - 585. [Abstract] [Full Text] [PDF]

				N. L. Bartlett, A. Younes, M. H. Carabasi, A. Forero, J. D. Rosenblatt, J. P. Leonard, S. H. Bernstein, R. G. Bociek, J. M. Lorenz, B. W. Hart, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies Blood, February 15, 2008; 111(4): 1848 - 1854. [Abstract] [Full Text] [PDF]

				B. Hirsch, M. Hummel, S. Bentink, F. Fouladi, R. Spang, R. Zollinger, H. Stein, and H. Durkop CD30-Induced Signaling Is Absent in Hodgkin's Cells but Present in Anaplastic Large Cell Lymphoma Cells Am. J. Pathol., February 1, 2008; 172(2): 510 - 520. [Abstract] [Full Text] [PDF]

				S. M. Horwitz Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas Hematology, January 1, 2008; 2008(1): 289 - 296. [Abstract] [Full Text] [PDF]

				M. Crump Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant Hematology, January 1, 2008; 2008(1): 326 - 333. [Abstract] [Full Text] [PDF]